Analysis of RATS, VATS and Open Lung Resections After Neoadjuvant Chemo-immunotherapy in Patients Performed in Five Referred Centers
Recruiting · NCT06626243 · Observational (researchers observe without assigning treatment) · Lead sponsor: Scientific Institute San Raffaele
View the official record on ClinicalTrials.gov →What this trial is about
The study is a retrospective observational study. The study is designed to be multicentric and international and it will analyze medical records from selected patients diagnosed with locally advanced and resectable NSCLC who underwent lung resection by robotic, VATS and open approach after receiving neoadjuvant chemo-immunotherapy. There are no risks for the patients, as this is a retrospective data collection.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Diagnosis of clinical or pathological stage IIB (T1-2, hilar N1, M0) and III (any T, N1-2, M0) NSCLC surgically treated with robotic, VATS and open approach with radical intent from 1st of January 2016 to 31st of March 2024
- Received neoadjuvant chemo-immunotherapy or immunotherapy alone
- Age \>= 18 years old at the moment of surgery
Exclusion criteria
- Age \<18 years old at the moment of surgery
Where it is running
6 locations listed across 3 US states.
- Baptist Health South Florida - Miami, Florida, United States
- Memorial Sloan Kettering Cancer Center - New York, New York, United States
- West Virginia University - Morgantown, West Virginia, United States
- Scientific Institute Ospedale San Raffaele - Milan, Italy
- Regina Elena National Cancer Institute - Rome, Italy
- Istituto Clinico Humanitas - Rozzano, Milan, Italy